Ocular Therapeutix shares have dropped 18.5% over the past six months to $10.37, underperforming the S&P 500's 7.8% gain. The company's revenue has declined at an annualized rate of 6.7% over the last two years, while its adjusted operating margin and free cash flow margin for the trailing 12 months stand at negative 575% and negative 463%, respectively. StockStory analysts cite these deteriorating fundamentals as reasons to avoid the stock, noting that the market expects continued losses and that the forward price-to-sales ratio of 42.4 times offers limited upside relative to the potential downside.
Ocular Therapeutix IncRevenue decline, negative margins, and analyst downgrade based on deteriorating fundamentals.